Similar effects of recombinant interferon-α-2b and natural interferon-α when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma

Liver International

Volumn 27, Issue 9, 2007, Pages 1209-1216

  Uka, Kiminori ^a   Aikata, Hiroshi ^a   Takaki, Shintaro ^a   Miki, Daiki ^a   Jeong, Soo Cheol ^a   Hiramatsu, Akira ^a   Kodama, Hideaki ^a   Shirakawa, Hiroo ^a   Kawakami, Yoshiiku ^a   Takahashi, Shoichi ^a   Toyota, Naoyuki ^b   Ito, Katsuhide ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Advanced hepatocellular carcinoma; Natural interferon ; Recombinant interferon 2b

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CHLOROTRIANISENE; CISPLATIN; FLUOROURACIL; IODINATED POPPYSEED OIL; OIF; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTERY CATHETERIZATION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG RESPONSE; FALSE ANEURYSM; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NAUSEA; PORTAL VEIN THROMBOSIS; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR THROMBUS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON ALFA-2B; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; THERAPEUTIC EQUIVALENCY;

EID: 35148870112     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01554.x     Document Type: Article

References (43)

1. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459-65.
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
3. Health and welfare statistics association: Health and welfare statistics. J Health Welfare Stat 2000; 47: 421.
4. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
5. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
6. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-20.
7. Kamada K, Kitamoto M, Aikata H, et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-90.
8. Friedman M. Primary hepatocellular cancer-present results and future prospects. Int J Radiat Oncol Biol Phys 1983; 9: 1841-50.
9. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin, and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39-47.
10. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
11. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
12. Osterborg A, Engman K, Bjoreman M, et al. Patients treated with natural (leukocyte-derived) interferon (IFN)-alpha do not develop IFN antibodies. Eur J Haematol 1991; 47: 234-5.
13. Ronnblom LE, Janson ET, Perers A, Oberg KE, Alm GV. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 1992; 89: 330-5.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST) guidelines. J Natl Cancer Inst 2000; 92: 205-16.
16. NCI Common Toxicity Criteria. http://ctep.cancer.gov/reporting/ cancer.gov/reporting/ctc.html
17. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997; 79: 2087-94.
18. Patt YZ, Yoffe B, Charnsangavej C, et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993; 72: 2574-82.
19. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/ β signalling to p53 responses in tumor suppression and antiviral defence. Nature 2003; 424: 516-23.
20. Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 2006; 43: 1074-83.
21. Nakaji M, Yano Y, Ninomiya T, et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389-97.
22. Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18: 2798-810.
23. Yano H, Iemura A, Haramaki M, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29: 1708-17.
24. Lindahl P, Learv R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69: 721-5.
25. Trinchieri G, Santoli D, Koprowski H. Spontaneous cell-mediated cytotoxicity in humans; role of interferon and immunoglobulins. J Immunol 1978; 120: 1849-55.
26. Horowitz RW, Heerdt BG, Hu X, Schwartz EL, Wadler S. Combination therapy with 5-fluorouracil and IFN-alpha 2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 1997; 3: 1317-22.
27. Grander D, Xu B, Einhorn S. Cytotoxic effect of interferon on primary malignant tumor cells. Studies in various malignancies. Eur J Cancer 1993; 29A: 1940-3.
28. Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 1992; 50: 1-9.
29. Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman RB. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983; 31: 285-9.
30. + T cells. J Exp Med 1993; 178: 1655-63.
31. Uno K, Shimizu S, Ido M, et al. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res 1985; 45: 1320-7.
32. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG. Synergistic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999; 101: 82-8.
33. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473-86.
34. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989; 163: 867-74.
35. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182: 1232-9.
36. Miyamoto A, Umeshita K, Sakon M, et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15: 1447-51.
37. Yamamoto T, Nagano H, Sakon M, et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7884-95.
38. Allen G, Diaz MO. Nomenclature of the human interferon proteins. J Interferon Res 1994; 14: 223-6.
39. Foster GR, Rodrigues O, Ghouze F, et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996; 16: 1027-33.
40. Yanai Y, Horie S, Yamamoto K, et al. Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 2001; 21: 1129-36.
41. Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial. Br J Cancer 1989; 60: 928.
42. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993; 17: 389.
43. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54.